These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37841851)

  • 1. Longitudinal Microbial and Molecular Dynamics in the Cystic Fibrosis Lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
    Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
    Res Sq; 2023 Sep; ():. PubMed ID: 37841851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor-Tezacaftor-Ivacaftor therapy.
    Martin C; Guzior DV; Gonzalez CT; Okros M; Mielke J; Padillo L; Querido G; Gil M; Thomas R; McClelland M; Conrad D; Widder S; Quinn RA
    Respir Res; 2023 Dec; 24(1):317. PubMed ID: 38104128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung.
    Sosinski LM; H CM; Neugebauer KA; Ghuneim LJ; Guzior DV; Castillo-Bahena A; Mielke J; Thomas R; McClelland M; Conrad D; Quinn RA
    J Cyst Fibros; 2022 Nov; 21(6):996-1005. PubMed ID: 34824018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study.
    Fila L; Grandcourtova A; Bilkova A; Drevinek P
    Front Pharmacol; 2023; 14():1178009. PubMed ID: 37332357
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
    Schaupp L; Addante A; Völler M; Fentker K; Kuppe A; Bardua M; Duerr J; Piehler L; Röhmel J; Thee S; Kirchner M; Ziehm M; Lauster D; Haag R; Gradzielski M; Stahl M; Mertins P; Boutin S; Graeber SY; Mall MA
    Eur Respir J; 2023 Aug; 62(2):. PubMed ID: 37414422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elexacaftor-tezacaftor-ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis.
    Zemke AC; Hilliam Y; Stapleton AL; Kimple AJ; Goralski JL; Shaffer AD; Pilewski JM; Senior BA; Lee SE; Cooper VS
    Int Forum Allergy Rhinol; 2024 May; 14(5):928-938. PubMed ID: 37837613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on the oropharyngeal metagenome in adolescents with cystic fibrosis.
    Steinberg R; Moeller A; Gisler A; Mostacci N; Hilty M; Usemann J
    J Cyst Fibros; 2024 Oct; ():. PubMed ID: 39406574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature.
    Tupayachi Ortiz MG; Baumlin N; Yoshida M; Salathe M
    Heliyon; 2024 Mar; 10(5):e26955. PubMed ID: 38463894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor.
    Gruber W; Stehling F; Blosch C; Dillenhoefer S; Olivier M; Brinkmann F; Koerner-Rettberg C; Sutharsan S; Mellies U; Taube C; Welsner M
    Front Sports Act Living; 2024; 6():1284878. PubMed ID: 38463712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elexacaftor-Tezacaftor-Ivacaftor Therapy for Chronic Sinus Disease in Cystic Fibrosis.
    Sheikh S; Ho ML; Eisner M; Gushue C; Paul G; Holtzlander M; Johnson T; McCoy KS; Lind M
    JAMA Otolaryngol Head Neck Surg; 2023 Dec; 149(12):1075-1082. PubMed ID: 37676668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity.
    Schütz K; Pallenberg ST; Kontsendorn J; DeLuca D; Sukdolak C; Minso R; Büttner T; Wetzke M; Dopfer C; Sauer-Heilborn A; Ringshausen FC; Junge S; Tümmler B; Hansen G; Dittrich AM
    Front Pharmacol; 2023; 14():1171544. PubMed ID: 37469865
    [No Abstract]   [Full Text] [Related]  

  • 13. Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the
    Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Ferrillo L; Pepe A; Francalanci M; Taccetti G; Buonaurio S; Celardo A; Salvadori L; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.
    Cavinato L; Luly FR; Pastore V; Chiappetta D; Sangiorgi G; Ferrara E; Baiocchi P; Mandarello G; Cimino G; Del Porto P; Ascenzioni F
    Eur Respir J; 2023 Apr; 61(4):. PubMed ID: 36455959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy.
    Westhölter D; Raspe J; Uebner H; Pipping J; Schmitz M; Straßburg S; Sutharsan S; Welsner M; Taube C; Reuter S
    Front Immunol; 2023; 14():1107437. PubMed ID: 36875141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosis.
    Gushue C; Eisner M; Bai S; Johnson T; Holtzlander M; McCoy K; Sheikh S
    Pediatr Pulmonol; 2023 Aug; 58(8):2308-2316. PubMed ID: 37222417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis.
    Casey M; Gabillard-Lefort C; McElvaney OF; McElvaney OJ; Carroll T; Heeney RC; Gunaratnam C; Reeves EP; Murphy MP; McElvaney NG
    Thorax; 2023 Aug; 78(8):835-839. PubMed ID: 37208188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist.
    Nichols DP; Morgan SJ; Skalland M; Vo AT; Van Dalfsen JM; Singh SB; Ni W; Hoffman LR; McGeer K; Heltshe SL; Clancy JP; Rowe SM; Jorth P; Singh PK;
    J Clin Invest; 2023 May; 133(10):. PubMed ID: 36976651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically Based Pharmacokinetic Modeling To Guide Management of Drug Interactions between Elexacaftor-Tezacaftor-Ivacaftor and Antibiotics for the Treatment of Nontuberculous Mycobacteria.
    Hong E; Almond LM; Chung PS; Rao AP; Beringer PM
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0110422. PubMed ID: 36286508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry.
    Sutharsan S; Dillenhoefer S; Welsner M; Stehling F; Brinkmann F; Burkhart M; Ellemunter H; Dittrich AM; Smaczny C; Eickmeier O; Kappler M; Schwarz C; Sieber S; Naehrig S; Naehrlich L;
    Lancet Reg Health Eur; 2023 Sep; 32():100690. PubMed ID: 37554663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.